A latex slide agglutination test for rapid detection of antimyeloperoxidase antibody

K H Ko, S S Lee, J W M Lawton

Abstract

**Aim**—To develop and test a new latex slide agglutination test (MPO-LSAT) to detect antimyeloperoxidase (anti-MPO) antibody in serum.

**Methods**—Latex bead coating was adjusted to give maximum sensitivity by attending to latex size, MPO to latex ratio for coupling, ratio of diluted serum to MPO-latex, reaction time and temperature for coupling, and reaction time for agglutination. Inhibition studies were performed using MPO, proteinase 3, bactericidal/permeability increasing protein, and lactoferrin.

**Results**—There was very good correlation between this test and the conventional anti-MPO enzyme linked immunosorbent assay (ELISA): 81% of sera positive in the ELISA were positive by MPO-LSAT. MPO-LSAT results correlated better with IgM anti-MPO than with IgG anti-MPO.

**Conclusions**—MPO-LSAT is a simple diagnostic test that is potentially useful in the clinical laboratory as a rapid screening tool for vasculitic diseases.

(J Clin Pathol 1999;52:770–772)

Keywords: latex agglutination; antineutrophil cytoplasmic antibody; anti-MPO antibody

Antineutrophil cytoplasmic antibody (ANCA) comprises a group of autoantibodies first reported by Davies et al in 1982.1 Its association with systemic vasculitis and the classification into C-ANCA and P-ANCA forms have become established.2 Up to now, indirect immunofluorescence has remained the standard method for ANCA detection, using cyto centrifuged, alcohol fixed human neutrophils as substrate. Myeloperoxidase (MPO), one major target antigen of ANCA found in some vasculitic diseases, such as necrotising and crescentic glomerulonephritis and microscopic polyarteritis,3,4 is detected by enzyme linked immunosorbent assay (ELISA). Some patients with anti-MPO, in particular those with pulmonary–renal syndrome, have life threatening disease. Early detection of these antibodies is extremely useful in establishing an early diagnosis and guiding prompt treatment.

Passive latex agglutination is a simple method widely used in diagnostic laboratories. In this study we set out to develop a new latex slide test to detect anti-MPO, and to compare its performance with the established ELISA system.

Methods

**SERUM SAMPLES AND IMMUNOFLUORESCENCE**

Sera received at the immunology laboratory, Queen Mary Hospital, Hong Kong were first screened for ANCA by immunofluorescence. Positive results were distinguished by their pattern: either perinuclear staining (P-ANCA) or cytoplasmic staining (C-ANCA). Seventy-three P-ANCA positive sera (43 anti-MPO IgG positive, 30 anti-MPO IgG negative), 40 C-ANCA positive sera, and 40 ANCA negative sera from normal individuals were collected for testing. The method of immunofluorescence was as described in the First International Workshop on ANCA.5

**ANTI-MPO ELISA**

Neutrophil MPO (Calbiochem) was coated onto Immulon 2 microtitre plates (Dynex) at a concentration of 1.25 µg/ml in 0.05 M bicarbonate buffer, pH 9.5. After washing three times with 0.05% Tween 20 in phosphate buffer saline (PBS) and blocking with 1% bovine serum albumin in PBS with 0.05% Tween 20, 100 µl serum diluted 1:40 in the same buffer were added and incubated for one hour at 25°C, followed by washing. Alkaline phosphatase conjugated goat antihuman IgG or IgM (Biosource) diluted 1:1000 was added and incubated for one hour at 25°C, followed by the substrate p-nitrophenyl phosphate for 15 minutes. The absorbance was read at 405 nm optical density. Results were expressed as a percentage of an international standard reference serum, which had been serially diluted to obtain a standard curve in each assay. Normal cut off value was established by calculating the mean per cent plus 3 SD of 56 normal samples.

**ANTI-MPO LATEX TEST**

The latex bead coating method was modified from that of Goode et al.7 The following conditions were adjusted to give maximum sensitivity: latex size; MPO to latex ratio for coupling; ratio of diluted serum to MPO–latex; reaction time and temperature for coupling; reaction time for agglutination. Inhibition studies were performed using MPO, proteinase 3, bactericidal/permeability increasing protein, and lactoferrin.

One hundred microlitres of MPO at 0.5 mg/ml concentration (Calbiochem) were mixed with 50 µl 10% (vol/vol) carbonate modified latex beads, 0.8 µm diameter (Sigma) in 0.1 M phosphate buffer for 10 minutes at 25°C. Then 50 µl of 15% (wt/vol) L-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulphonate (Sigma) were added to covalently bind MPO to the latex particles. The mixture was put on a roller-mixer for two hours and centrifuged, alcohol fixed human neutrophils were mixed with 1% bovine serum albumin in PBS and blocked with 1% Tween 20. The latex bead coating method was modified from that of Goode et al.7

5. Goode et al. Workshop on ANCA.5
6. The following conditions were adjusted to give maximum sensitivity: latex size; MPO to latex ratio for coupling; ratio of diluted serum to MPO–latex; reaction time and temperature for coupling; reaction time for agglutination. Inhibition studies were performed using MPO, proteinase 3, bactericidal/permeability increasing protein, and lactoferrin.

J Clin Pathol 1999;52:770–772
at 25°C. After washing three times in glycine
buffer (1% bovine serum albumin in glycine
buffered saline, pH 8, with 0.1% Tween 20),
coated latex was suspended in glycine buffer at
a concentration of 0.5%. MPO coated latex
was stored at 4°C until use.

Serum anti-MPO was detected by passive
slide agglutination. Briefly, 5 µl of MPO–latex
were added to 10 µl diluted serum on the dark
background glass slide. After rotating the glass
slide for two minutes by hand, the agglutina-
tion was read by eye. The strength of
agglutination was graded as −, +/−, +, ++, or
+++.

All sera were tested neat and at 1/4 dilution
to exclude “prozone effect.” Positive sera were
then further titrated by twofold serial dilution
to determine the titre.

Results
The development of the new anti-MPO latex
agglutination test required optimisation of the
assay conditions. The single most important
factor was establishment of the optimum MPO
to latex concentration ratio. Owing to potential
batch variation, titration of MPO was neces-
sary for each new batch. For this batch of
MPO, a combination of 100 µl MPO (0.5
mg/ml) and 50 µl latex (10%) gave the best
results. The stability of MPO–latex during
storage was monitored by sequential testing of
aliquots of standard anti-MPO positive serum,
stored at −70°C. MPO–latex was found to be
stable at 4°C, without any change of titre of
reference serum, for at least six months (data
not shown).

In terms of positivity and negativity, correla-
tion of the MPO-LSAT with the conventional
ELISA was excellent. However, absolute values
correlated only weakly in the IgM assay (fig 1).
MPO-LSAT did not react with normal human
sera, anti-MPO negative P-ANCA sera, and
C-ANCA positive sera except for one sample
(table 1). The latter belonged to a C-ANCA
positive patient and tested strongly positive for
anti-MPO IgM (binding activity > 100%). In
P-ANCA positive sera, 35 of 43 anti-MPO IgG
positive samples were detected by MPO-LSAT.
Agglutination negative samples had low MPO
binding in the IgG ELISA (binding activity
< 6%) and no significant activity in the IgM
anti-MPO ELISA. Thus, using MPO IgG
ELISA results as the reference, the sensitiv-
ty of MPO-LSAT was 81%.

It was confirmed that MPO–latex was
specifically agglutinated by anti-MPO, but not
by anti-PR3, anti-bactericidal/permeability in-
creasing protein (BPI) or anti-lactoferrin. This
agglutination ability of anti-MPO could be
inhibited by MPO but not by PR3, BPI, or
lactoferrin.

A sample strongly positive in MPO-LSAT
was further evaluated by serial dilution. MPO–
latex did not agglutinate in the neat serum,
owing to the prozone effect. In view of this
phenomenon, a 1/4 dilution of test serum was
routinely included in MPO-LSAT.

Finally, MPO–latex was agglutinated better
by IgG anti-MPO than by IgG. MPO-LSAT
titre (r = 0.51, p < 0.001) correlated with IgM
anti-MPO binding in ELISA but less so with
IgG anti-MPO (r = 0.12, p = 0.45) (fig 1).

Discussion
Patients with anti-MPO associated vasculitis
often present with severe illness, such as acute
renal failure. Access to early and reliable testing
is crucial in guiding subsequent clinical man-
agement. This is particularly important in
Hong Kong where anti-MPO is the common-
est autoantibody found in patients with small
vessel vasculitis. The development of the latex
test therefore contributes towards a more efficient and effective system in the diagnosis of anti-MPO positive vasculitis.

The new MPO-LSAT is a simple procedure, the performance of which is comparable with the conventional assay by ELISA. It is a rapid diagnostic tool, the results of which can be generated within minutes. Technically, the test is simple to perform and results are easy to read. The procedure’s speed and simplicity are particularly important when an urgent result is needed in a clinical laboratory.

To exclude confounding results in the presence of other autoantibodies, we tested 20 antinuclear antibody positive sera and 20 rheumatoid factor positive sera. All were negative by IgG anti-MPO ELISA. Two rheumatoid factor positive sera proved to be positive in the MPO-LSAT and the IgM anti-MPO ELISA. Thus rheumatoid factor may occasionally give rise to false positive results.

MPO-LSAT has a very high specificity and correlates positively with anti-MPO ELISA, especially with the ELISA for IgM. IgM anti-MPO antibody had been reported to be associated with clinical manifestation such as pulmonary haemorrhage but it is not commonly assayed in clinical laboratories. MPO-LSAT may prove to be a useful laboratory diagnostic tool in IgM anti-MPO associated disease. The stability of the test reagent and reproducibility of results add value to the simple assay system. Its preferential reaction with IgM anti-MPO would need to be further investigated to determine its clinical relevance.

A latex slide agglutination test for rapid detection of antmyeloperoxidase antibody.

K H Ko, S S Lee and J W Lawton

*J Clin Pathol* 1999 52: 770-772
doi: 10.1136/jcp.52.10.770

Updated information and services can be found at:
http://jcp.bmj.com/content/52/10/770

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/